passiv
immunotherapi
mainli
use
therapi
cancer
inflammatori
condit
recent
studi
shown
monoclon
antibodi
mab
base
passiv
immunotherapi
promis
approach
combat
viru
infect
specif
mous
mab
routin
gener
larg
amount
use
hybridoma
technolog
use
therapi
human
be
due
immunogen
therefor
develop
chimer
human
mab
import
therapeut
purpos
facilit
varieti
molecular
techniqu
like
recombin
dna
technolog
better
understand
structur
function
antibodi
humanmous
chimer
form
allow
detail
analysi
mechan
inhibit
potenti
therapeut
applic
stepbystep
descript
convers
process
describ
commerci
avail
reagent
requir
step
mean
experiment
easili
set
research
laboratori
emil
von
behr
first
nobel
prize
medicin
demonstr
humor
immun
could
transfer
immun
anim
human
use
heterolog
sera
human
limit
immunolog
reaction
serum
protein
exampl
hypersensit
help
techniqu
better
purif
antibodi
monoclon
antibodi
mab
engin
overcom
mani
complic
attain
improv
specif
till
recent
main
focu
use
recombin
mab
passiv
immunotherapi
treatment
cancer
inflammatori
condit
mabbas
immunotherapi
becom
import
infecti
diseas
widespread
resist
drug
among
pathogen
immunocompromis
host
emerg
new
pathogen
control
pathogen
acut
cytopath
virus
caus
fatal
damag
infect
tissu
best
way
prevent
diseas
vaccin
alway
avail
suitabl
passiv
immunotherapi
could
use
provid
protect
period
highexposur
risk
immunotherapi
promis
approach
combat
viru
infect
much
research
effort
devot
gener
characteris
virusneutr
mab
mani
laboratori
hybridoma
clone
deriv
mous
rat
blymphocyt
fusion
myeloma
cell
line
eg
one
major
limit
use
hybridomaderiv
mab
humanantimous
humanantirat
antibodi
respons
occur
result
immunogen
mous
rat
antibodi
therefor
import
human
antibodi
human
therapeut
purpos
without
impact
bind
affin
toward
antigen
target
exampl
viru
research
mous
mab
select
potent
viru
neutral
activ
use
convert
humanmous
chimer
form
humanmous
chimer
form
similar
neutral
activ
reason
develop
therapeut
applic
henc
techniqu
convert
mous
mab
humanmous
chimer
form
emerg
research
tool
chimer
antibodi
success
produc
test
specif
bind
activ
mani
previou
studi
exampl
chimer
antihuman
mab
bind
antigen
demonstr
elisa
western
blot
addit
humanmous
chimer
antibodi
gener
mab
hepat
e
viru
hev
capsid
protein
still
maintain
bind
activ
similar
origin
mab
shown
elisa
western
blot
sinc
chimer
antibodi
expect
less
immunogen
human
could
suitabl
antibodi
therapi
viral
infect
inde
demonstr
patient
receiv
chimer
antibodi
show
toxic
allerg
reaction
chimer
antibodi
appear
significantli
less
immunogen
parent
murin
antibodi
construct
humanmous
chimer
antibodi
basic
involv
clone
ligat
variabl
region
gene
mous
mab
express
vector
heavyand
lightchain
immunoglobulin
constant
region
simpl
methodolog
convers
describ
stepbystep
manner
first
step
amplifi
heavyand
lightchain
immunoglobulin
variabl
region
use
polymeras
chain
reaction
pcr
obtain
firststrand
cdna
pcr
reaction
messeng
rna
mrna
need
extract
hybridoma
cell
revers
transcript
success
obtain
correct
sequenc
mainli
depend
select
primer
set
optimis
condit
pcr
reaction
differ
primer
set
develop
amplifi
variabl
domain
mous
igprim
set
also
commerci
avail
exampl
one
novagen
success
appli
mani
previou
studi
eg
order
determin
sequenc
dna
product
pcr
blunt
end
ligat
dna
topoisomeras
provid
effici
way
clone
dna
vector
use
polymeras
proofread
activ
significantli
reduc
chanc
mutat
introduc
pcr
amplif
step
sequenc
align
multipl
clone
also
easili
reveal
mismatch
found
rare
clone
clone
ident
sequenc
obtain
howev
two
set
sequenc
obtain
like
hybridoma
cell
use
mrna
extract
heterogen
implic
hybridoma
cell
need
subclon
correct
sequenc
obtain
subclon
vector
contain
constant
region
human
heavi
light
chain
respect
figur
vector
design
mammalian
express
homemad
commerci
avail
exampl
latter
pair
vector
invivogen
express
humanmous
chimer
antibodi
achiev
transfect
vector
transfect
mammalian
cell
line
like
human
embryon
kidney
cell
hek
secret
antibodi
purifi
cultur
supernat
test
determin
still
retain
antigenbind
capac
chimer
direct
comparison
mous
monoclon
antibodi
produc
hybridoma
reveal
incompat
mous
variabl
human
constant
region
mousehuman
chimer
antibodi
previou
methodolog
summar
figur
use
convert
mous
mab
chimer
humanmous
form
mab
antibodi
gener
mice
sever
acut
respiratori
syndrom
coronaviru
sarscov
spike
protein
shown
figur
mous
chimer
abl
bind
spike
protein
hek
cell
lysat
transfect
plasmid
contain
fulllength
spike
gene
count
collect
iv
amplifi
region
use
expand
high
fidel
pcr
system
roch
note
add
novagen
ab
leader
primer
final
concentr
pmol
l
cg
leader
primer
pmol
l
option
add
novagen
primer
reach
final
concentr
pmol
l
v
run
dna
gel
electrophoresi
agaros
gel
pcr
product
extract
dna
band
around
bp
note
determin
generul
bp
dna
ladder
thermo
scientif
use
qiaex
ii
gel
extract
kit
qiagen
elut
dna
nucleasefre
water
ligat
potenti
amplifi
product
gel
extract
pcr
xgal
solut
thermo
scientif
incub
plate
overnight
c
ii
grow
bacteria
least
white
light
blue
coloni
lb
broth
contain
g
ml
ampicillin
hour
c
iii
collect
ml
bacteria
plasmid
extract
use
axyprep
plasmid
miniprep
kit
axygen
bioscienc
keep
bacteria
lb
broth
c
shortterm
storag
week
iv
cut
recombin
plasmid
l
fastdigest
restrict
enzym
ecori
thermo
scientif
run
dna
gel
electrophoresi
confirm
presenc
dna
insert
v
sequenc
recombin
plasmid
use
bigdy
termin
appli
biosystem
forward
primer
revers
primer
vi
verifi
correct
sequenc
align
sequenc
differ
clone
find
common
one
match
end
sequenc
novagen
primer
sequenc
check
earli
stop
codon
within
sequenc
perform
blastp
cell
lysat
separ
sdspage
gel
detect
use
mous
mab
humanmous
chimer
mab
via
western
blot
analysi
previous
describ
molecular
weight
marker
kilodalton
indic
left
search
sequenc
nonredund
databas
ncbi
note
transform
plasmid
invivogen
separ
e
coli
cell
invitrogen
obtain
desir
amount
plasmid
subsequ
digest
ligat
step
pick
one
transform
coloni
overnightincub
plate
grow
lb
broth
appropri
antibiot
g
ml
zeocin
invivogen
g
ml
blasticidin
hcl
invivogen
hour
c
collect
ml
bacteria
cultur
plasmid
extract
use
midiprep
kit
qiagen
ii
identifi
signal
peptid
end
signalp
http
wwwcbsdtudkservic
signalp
amplifi
variabl
region
without
signal
peptid
domain
use
expand
high
fidel
pcr
system
forward
revers
primer
bp
overlap
appropri
region
within
plu
bp
end
restrict
site
eg
ecori
nhei
ecori
bsiwi
note
bp
restrict
site
ensur
effici
digest
fastdigest
restrict
enzym
thermo
scientif
import
ensur
frameshift
ligat
pfuse
vector
iii
digest
pcramplifi
separ
use
fastdigest
restrict
enzym
eg
ecori
nhei
plasmid
pcramplifi
separ
use
fastdigest
restrict
enzym
eg
ecori
bsiwi
iv
run
dna
gel
electrophoresi
agaros
gel
purifi
digest
plasmid
pcr
product
extract
dna
use
qiaex
ii
gel
extract
kit
elut
dna
nucleasefre
water
v
clone
use
ligas
enzym
thermo
scientif
molar
ratio
dna
insert
vector
ligat
reaction
note
vi
transform
plasmid
ligat
step
cell
heat
shock
method
grow
lb
agar
plate
contain
g
ml
zeocin
lb
agar
plate
contain
g
ml
blasticidin
hcl
overnight
c
pick
sever
transform
coloni
plate
grow
lb
broth
appropri
antibiot
g
ml
zeocin
g
ml
blasticidin
hcl
vii
collect
ml
bacteria
plasmid
extract
use
axyprep
plasmid
miniprep
kit
keep
bacteria
lb
broth
c
shortterm
storag
week
viii
cut
recombin
plasmid
l
fastdigest
restrict
enzym
run
dna
gel
electrophoresi
confirm
presenc
dna
insert
ix
option
step
sequenc
dna
insert
recombin
plasmid
use
bigdy
termin
x
grow
bacteria
correct
recombin
plasmid
lb
broth
appropri
antibiot
g
ml
zeocin
g
ml
blasticidin
hcl
hour
c
collect
ml
bacteria
cultur
plasmid
extract
use
midiprep
kit
seed
million
human
embryon
kidney
cell
hek
invitrogen
cm
dish
nunc
ml
transfect
media
dulbecco
modifi
eagl
medium
dmem
invitrogen
fetal
bovin
serum
hyclon
overnight
c
co
note
ii
add
g
recombin
plasmid
l
lipofectamin
invitrogen
separ
tube
contain
l
optimem
invitrogen
vortex
briefli
incub
room
temperatur
rt
minut
iii
spin
briefli
mix
optimem
plasmid
lipofectamin
togeth
tube
incub
minut
rt
iv
aspir
cell
cultur
media
gentli
add
ml
transfect
media
mixtur
lipofectamin
plasmid
note
v
swirl
dish
gentli
mix
incub
hour
c
co
vi
gentli
aspir
media
dish
add
ml
fresh
transfect
media
incub
c
co
vii
collect
cell
cultur
supernat
three
time
everi
hour
replenish
fresh
transfect
media
time
keep
cell
cultur
supernat
c
use
immedi
